Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura
- Resource Type
- Article
- Authors
- Özcan, Fedai; Markau, Silke; Girndt, Matthias; Felten, Helmut; Hausberg, Martin; Brand, Marcus; Gerth, Jens; Bommer, Martin; Zschiedrich, Stefan; Schneider, Johanna; Elitok, Saban; Gawlik, Alexander; Schwenger, Vedat; Roeder, Maximilian; Radermacher, Jörg; Morgner, Anke; Herbst, Regina; von Auer, Charis; Völker, Linus A.; Kaufeld, Jessica; Balduin, Gesa; Merkel, Lena; Kühne, Lucas; Eichenauer, Dennis A.; Osterholt, Thomas; Hägele, Holger; Kann, Martin; Grundmann, Franziska; Kolbrink, Benedikt; Schulte, Kevin; Gäckler, Anja; Kribben, Andreas; Boss, Kristina; Potthoff, Sebastian A.; Rump, Lars C.; Schmidt, Tilman; Mühlfeld, Anja S.; Schulmann, Karsten; Hermann, Matthias; Gaedeke, Jens; Sauerland, Kristin; Bramstedt, Jörn; Hinkel, Ulrich P.; Miesbach, Wolfgang; Bauer, Frederic; Westhoff, Timm H.; Bruck, Heike; Buxhofer-Ausch, Veronika; Müller, Tobias J.; Wendt, Ralph; Harth, Ana; Schreiber, Adrian; Seelow, Evelyn; Tölle, Markus; Gohlisch, Christopher; Bieringer, Markus; Geuther, Gesa; Jabs, Wolfram J.; Fischereder, Michael; von Bergwelt-Baildon, Anke; Schönermarck, Ulf; Knoebl, Paul; Menne, Jan; Brinkkoetter, Paul T.
- Source
- In Journal of Thrombosis and Haemostasis March 2023 21(3):559-572
- Subject
- Language
- ISSN
- 1538-7836